GLP-1 Market
LLY $1427.28 ▼ -0.7% NVO $40.65 ▼ -1.1% PFE $28.83 ▼ -2.1% VKTX $27.58 ▼ -3.0% KLRA $13.21 ▼ -8.1% GPCR $19.84 ▼ -5.3% RHHBY $60.57 • 0.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Trevogrumab-Part A

Company
Regeneron Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
5 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

5 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 13, 2026

Find a Clinical Trial Near Me

See recruiting studies for Trevogrumab-Part A and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT04730622

    Study of Parameters of Osteosarcopenia in Patients With Hip Fracture

    Istituto Ortopedico Rizzoli 100 participants Est. completion 2026-12-31 1 site
    Osteoarthritis Other conditions: Osteoporotic Fracture of Femur
    View official trial listing →
  • Recruiting NCT NCT07047144

    A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

    Not yet reported Scholar Rock, Inc. 52 participants Est. completion 2029-03 23 sites
    Other conditions: Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin
    View official trial listing →
  • Recruiting NCT NCT07435129

    Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD

    Not yet reported Scholar Rock, Inc. 60 participants Est. completion 2028-12 1 site
    Other conditions: Facioscapulohumeral Muscular Dystrophy, FSHD
    View official trial listing →
  • Recruiting NCT NCT07443826

    CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy

    Not yet reported, Not yet reported Unlimited Biotechnology LLC 12 participants Est. completion 2028-06-30 1 site
    Other conditions: Age-related Muscle Decline
    View official trial listing →
  • Recruiting NCT NCT07487376

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults

    Not yet reported iBio, Inc. 32 participants Est. completion 2027-05 1 site
    Other conditions: Overweight , Obesity
    View official trial listing →
  • Completed NCT NCT01136083

    Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients

    Not yet reported National Taiwan University Hospital 60 participants Est. completion 2012-08 1 site
    Other conditions: Non-small-cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT01321320

    Investigation of the Role of FHL-1 and Myostatin in Intensive Care Unit Acquired Paresis (ICUAP)

    Not yet reported Imperial College London 13 participants Est. completion 2013-10 1 site
    Other conditions: Intensive Care Unit Acquired Paresis, Muscle Wasting
    View official trial listing →
  • Completed NCT NCT01507402

    A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

    Not yet reported Regeneron Pharmaceuticals 76 participants Est. completion 2012-11 2 sites Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01524224

    A Dose-Escalation Study in Participants With Advanced Cancer

    Not yet reported Eli Lilly and Company 29 participants Est. completion 2016-01 7 sites
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT01720576

    Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)

    Not yet reported Regeneron Pharmaceuticals 60 participants Est. completion 2013-06 2 sites Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01910220

    Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

    Not yet reported Regeneron Pharmaceuticals 125 participants Est. completion 2014-10 5 sites Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT01958970

    Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

    Not yet reported, Not yet reported Pinta Biotherapeutics 51 participants Est. completion 2016-01 6 sites
    Other conditions: End Stage Renal Disease, Kidney Disease, Protein Energy Wasting
    View official trial listing →
  • Completed NCT NCT01963598

    Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

    Not yet reported Regeneron Pharmaceuticals 253 participants Est. completion 2015-02 43 sites Stand-alone
    Other conditions: Sarcopenia
    View official trial listing →
  • Terminated NCT NCT02310763

    A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

    Not yet reported Pfizer 121 participants Est. completion 2018-11-23 66 sites
    Other conditions: Duchenne Muscular Dystrophy
    View official trial listing →
  • Status unknown NCT NCT02325245

    Effects of Metformin in Pre-frail Elderly

    Not yet reported Universitas Indonesia 150 participants Est. completion 2017-03 1 site
    Other conditions: Pre-frail Elderly
    View official trial listing →
  • Terminated NCT NCT02515669

    Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

    Not yet reported, Not yet reported Hoffmann-La Roche 43 participants Est. completion 2020-04-15 12 sites
    Other conditions: Muscular Dystrophy (DMD)
    View official trial listing →
  • Completed NCT NCT02741739

    Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects

    Not yet reported Regeneron Pharmaceuticals 28 participants Est. completion 2016-05 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT02907619

    An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

    Not yet reported Pfizer 59 participants Est. completion 2018-11-22 47 sites
    Other conditions: Duchenne Muscular Dystrophy
    View official trial listing →
  • Completed NCT NCT02943239

    Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

    Not yet reported Regeneron Pharmaceuticals 82 participants Est. completion 2019-04-30 2 sites Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT03162042

    Role of Myostatin, Activin A and Follistatin Cachexia of ENT Cancers

    University Hospital, Clermont-Ferrand 60 participants Est. completion 2017-05 1 site
    Other conditions: Cachexia, Squamous Cell Carcinoma, Head and Neck Cancer
    View official trial listing →
  • Terminated NCT NCT03172403

    Skeletal Muscle Expression of Myostatin and Cancer of Digestive System Associated Cachexia

    Not yet reported Centre Hospitalier Universitaire de Saint Etienne 3 participants Est. completion 2019-08-01 1 site
    Other conditions: Cancer of Digestive System
    View official trial listing →
  • Completed NCT NCT03244449

    New IR Biomarkers (Myokines) in Colombian People

    University of Los Andes, Columbia 81 participants Est. completion 2016-12-16
    Type 2 diabetes Other conditions: Insulin Resistance
    View official trial listing →
  • Withdrawn NCT NCT03710941

    Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

    Not yet reported Regeneron Pharmaceuticals Est. completion 2020-11-05 Stand-alone
    Other conditions: Sporadic Inclusion Body Myositis
    View official trial listing →
  • Completed NCT NCT03921528

    An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy

    Not yet reported Scholar Rock, Inc. 58 participants Est. completion 2024-02-28 16 sites
    Other conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations
    View official trial listing →
  • Completed NCT NCT04112875

    Effect of L-arginine on Microcirculation, Myogenesis and Angiogenesis Associated With Aging, Sarcopenia and Diabetes

    Not yet reported Rio de Janeiro State University 120 participants Est. completion 2019-09 1 site
    Type 2 diabetes Other conditions: Aging, Sarcopenia, Microcirculation
    View official trial listing →
  • Completed NCT NCT04246918

    Effect of BCAA Supplementation on Muscle Mass, Muscle Quality and Molecular Markers of Muscle Regeneration in CLD Patients

    Not yet reported Institute of Liver and Biliary Sciences, India 60 participants Est. completion 2022-09-30 1 site
    Other conditions: Chronic Liver Disease
    View official trial listing →
  • Completed NCT NCT04786522

    Irisin Levels in Patients With Charcot-Marie-Tooth (CMT) Disease

    University of Bari 20 participants Est. completion 2020-12-30 1 site
    Other conditions: Charcot-Marie-Tooth Disease
    View official trial listing →
  • Completed NCT NCT05156320

    Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

    Not yet reported Scholar Rock, Inc. 188 participants Est. completion 2024-12-18 50 sites
    Other conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
    View official trial listing →
  • Enrolling by invitation NCT NCT05521958

    Gene Expression in Lower Extremity Acute Traumatic Compartment Syndrome

    Not yet reported University of Utah 80 participants Est. completion 2028-06 1 site
    Other conditions: Tibial Shaft Fracture, Tibial Plateau Fracture
    View official trial listing →
  • Status unknown NCT NCT05573321

    The Effect of Blood Flow Restriction (Bfr) Exercise on Acute Systemic Myokine Levels in Healthy Trained Men

    Not yet reported Ege University 22 participants Est. completion 2023-06
    Other conditions: Muscle Hypotrophy
    View official trial listing →
  • Active, not recruiting NCT NCT05626855

    Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

    Not yet reported Scholar Rock, Inc. 238 participants Est. completion 2029-05-02 49 sites
    Other conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
    View official trial listing →
  • Completed NCT NCT06299098

    A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

    Not yet reported Regeneron Pharmaceuticals 1005 participants Est. completion 2026-10-21 60 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06445075

    Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

    Not yet reported Scholar Rock, Inc. 102 participants Est. completion 2025-06-17 7 sites
    Other conditions: Overweight and Obesity
    View official trial listing →
  • Completed NCT NCT06529627

    GDF-8 Levels in ICSI Cycles

    Not yet reported University of Alexandria 42 participants Est. completion 2024-01-31 1 site
    Other conditions: Infertility
    View official trial listing →
  • No Longer Available NCT NCT06877689

    EAP of Apitegromab for Patients With Spinal Muscular Atrophy

    Scholar Rock, Inc.
    Other conditions: SMA
    View official trial listing →
  • Active, not recruiting NCT NCT07281495

    Taldefgrobep Alfa in Adults With Overweight and Obesity

    Not yet reported Biohaven Therapeutics Ltd. 150 participants Est. completion 2026-09 20 sites
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07328789

    Factors Influencing Cardiac Rehabilitation Success

    Pomeranian Medical University Szczecin 150 participants Est. completion 2029-07-01
    Other conditions: Rehabilitation
    View official trial listing →
  • Completed NCT NCT07473440

    AEROBIC ADAPTATION AND BIOMARKER RESPONSES IN COMBAT ATHLETES

    Not yet reported Adiyaman University 40 participants Est. completion 2025-03-25 1 site
    Other conditions: Exercise Adaptation, Aerobic Capacity, Athletic Performance, Combat Sports Training
    View official trial listing →
  • Completed NCT NCT07476391

    Myostatin and Irisin Levels in Predicting the Outcome of Patients With Systemic Inflammation: A Prospective Observational Study

    Charles University, Czech Republic 54 participants Est. completion 2025-11-11 1 site
    Other conditions: Systemic Inflammatory Response Syndrome (SIRS)
    View official trial listing →
  • Not yet recruiting NCT NCT07519551

    Serum Myostatin and Irisin Levels in Postmenopausal Women: Association With Bone Mineral Density and Muscle Strength

    Kanuni Sultan Suleyman Training and Research Hospital 60 participants Est. completion 2026-05-30
    Other conditions: Osteoporosis, Osteopenia
    View official trial listing →
  • Completed NCT NCT07658261

    Combined Training (Strength and Endurance) and the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men

    Not yet reported Arya Habibi 36 participants Est. completion 2024-12-15 1 site
    Other conditions: Overweight (BMI > 25), Obesity (BMI>30)
    View official trial listing →
  • Active, not recruiting NCT NCT07804719

    Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's Syndrome

    Antalya Training and Research Hospital 120 participants Est. completion 2026-10-20 1 site
    Other conditions: Primary Sjögren Syndrome, Sarcopenia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Trevogrumab-Part A, REGN1033, GDF8, Trevogrumab-Part B and Part C

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.